Skip to main content

Advertisement

SpringerLink
Log in

Industry anger over stringent trial disclosure requirements

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Arguments over the WHO's request to register early-stage trials

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Meredith Wadman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wadman, M. Industry anger over stringent trial disclosure requirements. Nat Rev Drug Discov 5, 527–528 (2006). https://doi.org/10.1038/nrd2103

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2103

  • Springer Nature Limited

Search

Navigation